In:
International Journal of Cancer, Wiley, Vol. 134, No. 12 ( 2014-06-15), p. 2829-2840
Abstract:
What's new? Immune modulation, and the role of antibody therapy in enhancing cell‐based immunotherapy, are promising avenues for cancer research. But immune evasion by tumor cells is an ongoing challenge. In this study, the authors designed an “immunoligand,” which binds to both colon carcinoma antigen (CEA) and a cytotoxicity receptor on NK cells. This resulted in potent anti‐tumor activity in vitro and in vivo , and activated innate as well as adaptive immune cells. This approach represents a novel immunotherapeutic strategy for solid tumors.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink